RxDoctor Payments Data

Krishna Rocha Singh, MD

Interventional Cardiology · Springfield, ILNPI 1508948530

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (54.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 75.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $12,289 and has fallen 99.4% since, to $75 in 2024.

$25,183in general payments, 2019–2025

Across 35 payments — averaging $719.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$19K
  • Bard Peripheral Vascular, Inc.$4K
  • Philips North America LLC$2K
  • GE HealthCare$75
  • Integra Lifesciences Corporation$50
  • Welch Allyn$42
  • plus $17 from 1 others
$1,652,730in research payments, 2019–2025

Across 13 payments — averaging $127,133 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$1.6M
  • Boston Scientific$51K

What the payments were for

  • Consulting fees$9,20037%
  • Speaking & faculty fees$13,80055%
  • Travel & lodging$3781%
  • Food & beverage$1,7637%
  • Gifts$420%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,183 in reported general payments places this provider in the 80th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$20,912
Medicare patients
369
Services billed
570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin50$49,392
EntrestoSacubitril/Valsartan56$48,546
EliquisApixaban26$25,527
FarxigaDapagliflozin Propanediol25$15,205
Nitroglycerin PatchNitroglycerin22$1,652
Carvedilol77$810
Metoprolol Succinate60$692
Losartan Potassium54$371
Amlodipine Besylate83$341
Nitroglycerin15$335
Lisinopril41$194
Furosemide49$192
Chlorthalidone18$190
ClopidogrelClopidogrel Bisulfate34$187
Spironolactone47$169

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →